Sugai Chemical Industry Co., Ltd. (4120.T)
Wakayama, JP
Sugai Chemical Industry Co., Ltd. is a Japanese enterprise specializing in the production and distribution of a wide array of chemical products. The company supplies pharmaceutical intermediates vital for the creation of medicines targeting conditions such as circulatory, respiratory, and central nervous system disorders, as well as antimicrobial, antiviral, and anti-cancer treatments. Its product line also encompasses active ingredients and intermediates for agrochemicals like fungicides, insecticides, and herbicides, in addition to veterinary pharmaceuticals. Furthermore, Sugai Chemical provides functional chemicals utilized in optical and electronic materials, resins and monomers, cosmetics, and fragrances. Other offerings include intermediaries for dyes and pigments, alongside various surfactants. Founded in 1928, the company changed its name from Sugai Chemical Factory to its present form in 1952. Its corporate headquarters are situated in Wakayama, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.73% | +0.17% | +4.53% | -2.53% | +3.38% | +5.09% | +12.58% | +7.98% | +51.58% | +126.35% | -27.57% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%-2.9% Q1'26: +10.7% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%+27.0% ★ Q1'26: +2,315.1% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+15.8% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+7.7% Q1'26: +15.0% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+4.1% Q1'26: +12.6% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%+0.0% Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×1.43× Q1'26: 0.71× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-11 | A | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-01 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Masanori Shioji | Executive Officer, Deputy GM of Production HQ and GM Fukui Office & Quality Assurance Department | — | — |
| Masaru Yamabe | General Manager of Accounting Division | — | — |
| Osamu Noma | Chief Executive Officer, President & Representative Director | — | male |
| Shigeru Okuno | Executive Officer & GM of Technology Division | — | male |
| Takashi Shuji | MD, GM of Production Division & Wakayama Business Office and Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4120.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
